David Gómez-Almaguer
Universidad Autónoma de Nuevo León
401 Papers
1.3K Citations
David Gómez-Almaguer is an academic researcher from Universidad Autónoma de Nuevo León. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 30, co-authored 309 publications.
Chat about Author
Papers
High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
J. A. Fernández-Gutiérrez,O. A. Reyes-Cisneros,Mark R. Litzow,Lorena Bojalil-Alvarez,Elizabeth Garcia-Villaseñor,Eliezer Tomas Gomez Gomez,Iván Murrieta-Álvarez,David Gómez-Almaguer,César Homero Gutiérrez-Aguirre,Amado J Karduss-Urueta,Guillermo J. Ruiz-Delgado,Guillermo J. Ruiz-Argüelles +11 more
TL;DR: In this paper, the authors proposed a high-dose melphalan (HD-Mel) regimen for autografting patients with multiple myeloma using non-frozen hematopoietic stem cells.
5
Outpatient transplantation in the COVID-19 era: a single-center Latin American experience.
Perla R. Colunga-Pedraza,Julia E. Colunga-Pedraza,Jesús D. Meléndez-Flores,Mariana González-Treviño,Eugenia M. Ramos-Dávila,Andrés Gómez-De León,Samantha P. Peña-Lozano,Oscar González-Llano,Olga G. Cantú-Rodríguez,Mónica Bustillos-Muñoz,César Homero Gutiérrez-Aguirre,David Gómez-Almaguer,José Carlos Jaime-Pérez +12 more
•Journal Article
Guias nacionales de diagnóstico y tratamiento de linfoma no Hodgkin
Myrna G Candelaria,Eduardo Cervera-Ceballos,Abelardo Meneses-García,Alejandro Avilés-Salas,Carmen Lome-Maldonado,Alejandra Zárate-Osomo,Carlos Ortiz-Hidalgo,Leticia Rodríguez-Moguel,Enoe Enedina Quiñónez-Urrego,Patricia Ramos-Salazar,Mónica B. Romero-Guadarrama,César Lara-Torres,Rocío Ramírez-Aceves,Omar López-Navarro,Silvia Rivas-Vera,Iván Eudaldo Díaz-Meneses,Enrique Estrada-Lobato,José Cervera-Ceballos,Carlos Enrique Rojas-Marín,José Mario Hernández-Rodriguez,Berenice Pérez-López,David Gómez-Almaguer,Javier Altamirano-Ley,Patricia Baz,Luis Manuel Valero-Saldaña,José René Navarrete-Herrera,Francisco Gerardo Torres-Salgado,Pedro Solano-Murillo,María de Jesús Nambo-Lucio,Ramón Rivas-Llamas,Jorge Luis Aquino-Salgado,Elsa Verónica Ávila-Arreguín,Patricia Cortés-Esteban,Martha Lilia Chongo-Alfaro,Oscar de Jesús Pérez-Ramírez,Diana Vanesa Toledano-Cuevas,Lobato-Mendizábal E,Mario Alberto Martínez-Ramírez,Adrián Morales-Maravilla,Rosa Elena Sosa-Camas,Gladys P. Agreda-Vásquez,Alejandro Camacho-Hernández,Alvaro Aguayo-González,José Ramiro Espinoza-Zamora,Sergio Arturo Sánchez-Guerrero,Valentín Lozano-Zavaleta,Julio Edgar Selva-Pallares,Juan Manuel Hernández-Rodríguez,Mariela Cardiel-Silva,Manuel Héctor Castillo-Rivera,Luis Villela,Luis Martín Loarca-Piña,Hugo Zurita-Martínez,Juan Graham-Casassus,Patricio Azaola-Espinosa,Salvador Silva-López,Jorge Antonio Armenta-San Sebastián,Francisco Mijangos-Huesca,Jorge Eduardo Pérez-Osorio,Fernando Aldaco-Sarvide,Guillermo Castellanos,Ana Florencia Ramírez-Ibarguen,Nidia Zapata-Canto,Juan Rafael Labardini-Méndez +63 more
5
The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants.
David Gómez-Almaguer,Alberto Vazquez-Mellado,J R Navarro-Cabrera,V Abello-Polo,Vera Milovic,Juan José García,Ana Lisa Basquiera,Silvia Saba,G Balladares,Jorge Vela-Ojeda,S Gómez,A Karduss-Aurueta,A Bustinza-Álvarez,Alejandro Requejo,Leonardo Feldman,José Carlos Jaime-Pérez,Sebastian Yantorno,Gustavo Kusminsky,César Homero Gutiérrez-Aguirre,Jorge Arbelbide,Juliana Martinez-Rolón,Gustavo Jarchum,Gregorio Jaimovich,Leandro Riera,E Pedraza-Mesa,L Villamizar-Gómez,Miguel Angel Herrera-Rojas,M M Gamboa-Alonso,Cecilia Foncuberta,G Rodríguez-González,M A García Ruiz-Esparza,E Hernández-Maldonado,M Paz-Infanzón,Elias Eugenio Gonzalez-Lopez,Guillermo J Ruiz-Argüelles +34 more
TL;DR: BM as a source of cells and ATG-based regimens should be standard because of higher GvHD incidence with PBSCs, although the latter combining with ATG in the conditioning regimen could be an option in selected high-risk patients.
5
Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience.
Julia E. Colunga-Pedraza,Oscar González-Llano,Carlos Eugenio González‐Martinez,David Gómez-Almaguer,José Miguel Yáñez-Reyes,Valentine Jiménez-Antolinez,Perla R. Colunga-Pedraza +6 more
TL;DR: This BZ‐based protocol is effective and safe when administered as an outpatient regimen and feasible in a low resource setting.
5